BOSTON & ST. LOUIS– Omniose, a company developing polysaccharide conjugate vaccines against serious bacterial threats, announced today the expansion of the leadership team to include Timothy Cooke, Ph.D., MBA as Chief Executive Officer and Roman Fleck. Ph.D., MBA as Chairperson. Dr. Cooke has over 30 years of experience in the vaccine industry and is active in vaccine policy roles, including the Biotechnology Industry Representative to the US National Vaccine Advisory Committee and Observer to the WHO Technical Advisory Group on Vaccines and Antimicrobial Resistance. Dr. Fleck is a seasoned entrepreneur & venture investor with over 20 years of experience in the biotech industry. The research team will be led by Christian Harding, Ph.D., Chief Scientific Officer and Co-Founder of Omniose.
Omniose is also announcing the formation of its Scientific Advisory Board including Mario Feldman, Ph.D., a Co-Founder and pioneer in engineering glycoconjugate vaccines using enzymatic conjugation, Viliam Pavliak, Ph.D., who has deep industry expertise in conjugate vaccine development at Wyeth/Pfizer, and Steven Projan, Ph.D., who brings broad industry experience in infectious disease, drug and vaccine development at MedImmune, Novartis and Wyeth/Pfizer.
“Omniose combines great science with a dedicated team on a mission to protect people from serious bacterial infections,” said Timothy Cooke, CEO. “Our approach greatly expands the universe of bacterial targets that can be addressed by bioconjugate vaccines.”
